Spago Nanomedical AB Logo

Spago Nanomedical AB

Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.

SPAGO | ST

Overview

Corporate Details

ISIN(s):
SE0004899474 (+2 more)
LEI:
549300DNLTVJ4OGO5X40
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Spago Nanomedical AB is a clinical-stage nanomedicine company developing products for the precise diagnosis and treatment of cancer and other severe diseases. The company's development is based on a proprietary platform of polymeric materials. Its portfolio includes two primary projects: Tumorad®, a targeted radionuclide therapy program, and SpagoPix, a novel MRI contrast agent. The Tumorad® candidate, 177Lu-SN201, is in Phase I/IIa clinical trials for treating advanced cancers by accumulating in tumors. The SpagoPix candidate, pegfosimer manganese, is designed to provide selective contrast enhancement in tumors and other tissues, with clinical data showing efficacy in breast cancer and endometriosis lesions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Spago Nanomedical AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Spago Nanomedical AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Spago Nanomedical AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America 950220
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden NEWBRY
New Nordic Healthbrands AB Logo
Develops and markets herbal supplements & beauty products for natural wellness consumers globally.
Sweden NNH
Newron Pharmaceuticals S.p.A. Logo
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
Italy NWRN
NextCell Pharma AB Logo
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
Sweden NXTCL
NGeneBio Co., Ltd. Logo
Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.
South Korea 354200
NIBEC CO., LTD. Logo
Biotech CDMO creating regenerative products with peptide and biomaterial technologies.
South Korea 138610
NIPPON CHEMIPHAR CO., LTD. Logo
Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.
Japan 4539
Nippon Shinyaku Co.,Ltd. Logo
Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.
Japan 4516
NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea 182400

Talk to a Data Expert

Have a question? We'll get back to you promptly.